Clinical Trial Update: Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Momordica charantia combined with dihydroartemisinin-piperaquine-primaquine for uncomplicated Plasmodium falciparum malaria …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uncomplicated Plasmodium Falciparum Malaria

Drugs mentioned

• Momordica charantia (Momordica charantia)
• dihydroartemisinin-piperaquine-primaquine (dihydroartemisinin-piperaquine-primaquine)

Snippet

Sponsor: Syamsudin Abdillah,Ph.D, Pharm D | Conditions: Uncomplicated Plasmodium Falciparum | Phase 2 | Status: COMPLETED